Thematic Poster
Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Phenotype characterization of non-cystic fibrosis bronchiectasis in India.
R. Dhar(Kolkata (West Bengal), India)
COI
1
PROGNOSIS - the German Bronchiectasis Registry: first results
F. Ringshausen(Hannover, Germany)
COI
2
The effect of gender on sputum microbiological profile in non-cystic fibrosis bronchiectasis
K. Lee(London, United Kingdom)
COI
3
Non-cystic fibrosis bronchiectasis: etiology and predictors of exacerbations and mortality in patients across the largest health system in central and western Massachusetts
J. Lee(Providence, United States)
COI
4
Neutrophil extracellular trap formation in peripheral blood and airway neutrophils in bronchiectasis and CF
H. Keir(Dundee (Angus), United Kingdom)
COI
5
Open label case-control study to assess Pidotimod efficacy in Non CF Bronchiectasis Disease: a pilot study
M. D'Amato(Napoli (NA), Italy)
COI
6
Aetiology of non-CF bronchiectasis in adults and its association to quality of life
L. Terpstra(Alkmaar (NH), Netherlands)
COI
7
Chronic lobe collapse: another bronchiectasis phenotype or a marker of Pseudomonas colonisation?
O. Munteanu(Chișinău (Chișinău), Republic of Moldova)
COI
8
The pulmonary microbiome in non-cystic fibrosis bronchiectasis.
M. Mac Aogáin(Dublin, Ireland)
COI
9
RISK FACTORS FOR ISOLATION MULTIDRUG-RESISTANT PATHOGENS IN BRONCHIECTASIS EXACERBATIONS
E. Amara Elori(Valencia, Spain)
COI
10
High frequencies of Aspergillus colonization and associated inflammation in stable bronchiectasis
M. Mac Aogáin(Dublin, Ireland)
COI
11
Bronchospasm secondary to nebulised antibiotics in bronchiectasis
R. Njafuh(Southsea (Hampshire), United Kingdom)
COI
12
Adherence in bronchiectasis (BQ) and concordance between multidimensional scales in a cohort of patients colonized by Pseudomonas aeruginosa (PsA).
E. Garcia Cortacero(Granada, Spain)
COI
13
Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry
B. Herrero Cortina(Zaragoza, Spain)
COI
14
Non-tuberculous mycobacteria – number of drugs and duration of treatment – does it matter?
J. Ibrahim(Walsall (West Midlands), United Kingdom)
COI
15
The efficacy, safety and feasibility of inhaled amikacin for the treatment of refractory non-tuberculous mycobacterial lung diseases
K. Yagi(Tokyo, Japan)
COI
16
Five year Cohort Analysis of Non-Tuberculosis Mycobacterium Lung Disease at a Tertiary Referral Centre
H. Kunst(London, United Kingdom)
COI
17
Long-term Outcome of Pulmonary Resection for Nontuberculous Mycobacterial Pulmonary Disease
T. Asakura(Tokyo, Japan)
COI
18
Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease; cross-sectional study
S. Suzuki(Tokyo, Japan)
COI
19
Non Tuberculous Mycobacteria in Calabria region: a retrospective cross-sectional study.
L. Surace(Lamezia Terme (CZ), Italy)
COI
20
. . .
